Special Issue

Pharmaceutical Strategy for Mood Disorders

Message from the Guest Editors

Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), are leading causes of disability worldwide, significantly affecting quality of life and health outcomes. Traditional treatments rely on mood stabilizers and atypical antipsychotics, but recent research has expanded therapeutic options. This Special Issue will explore key aspects of pharmaceutical strategies for mood disorders, including:

- Novel pharmacological targets and mechanisms;
- Personalized pharmacotherapy in special populations;
- Inflammation and neuroimmune interactions;
- Gut-brain axis and microbiome-based interventions;
- Polypharmacy and augmentation strategies;
- Pharmacogenetic and biomarker-driven treatment approaches;
- Clinical factors that optimize treatment response (e.g., adherence, metabolism, and lifestyle);
- Psychopathological dimensions associated with treatment beyond symptom reduction, including cognition and quality of life.

Guest Editors

Dr. Delfina Janiri

- 1. Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
- 2. Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, 00168 Rome, Italy

Dr. Alexia Koukopoulos

Department of Life Science, Health, and Health Professions, Link Campus University, 00165 Rome, Italy

Deadline for manuscript submissions

closed (22 September 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/232962

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

